# Inmune Bio, Inc. (INMB) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Inmune Bio, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/INMB/mda/fy2025/): filed 2026-03-30; accession 0001213900-26-036370 (https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm); latest 10-K
- [FY 2024 MD&A](/company/INMB/mda/fy2024/): filed 2025-03-27; accession 0001013762-25-003354 (https://www.sec.gov/Archives/edgar/data/1711754/000101376225003354/ea0229965-10k_inmune.htm)
- [FY 2023 MD&A](/company/INMB/mda/fy2023/): filed 2024-03-28; accession 0001213900-24-027206 (https://www.sec.gov/Archives/edgar/data/1711754/000121390024027206/ea0201084-10k_inmune.htm)
- [FY 2022 MD&A](/company/INMB/mda/fy2022/): filed 2023-03-02; accession 0001213900-23-016875 (https://www.sec.gov/Archives/edgar/data/1711754/000121390023016875/f10k2022_inmunebioinc.htm)
- [FY 2021 MD&A](/company/INMB/mda/fy2021/): filed 2022-03-03; accession 0001213900-22-010573 (https://www.sec.gov/Archives/edgar/data/1711754/000121390022010573/f10k2021_inmunebioinc.htm)

Back to /company/INMB/